263 related articles for article (PubMed ID: 36451132)
1. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
Yang Y; Zhang G; Hu C; Luo W; Jiang H; Liu S; Yang H
BMC Urol; 2022 Nov; 22(1):196. PubMed ID: 36451132
[TBL] [Abstract][Full Text] [Related]
2. The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.
Ball MW; Gorin MA; Drake CG; Hammers HJ; Allaf ME
Eur Urol Focus; 2017 Dec; 3(6):584-589. PubMed ID: 28753846
[TBL] [Abstract][Full Text] [Related]
3. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract][Full Text] [Related]
4. An Integrated Systematic Analysis and the Clinical Significance of Hepcidin in Common Malignancies of the Male Genitourinary System.
Wang X; Shi Q; Gong P; Zhou C; Cao Y
Front Genet; 2022; 13():771344. PubMed ID: 35646093
[TBL] [Abstract][Full Text] [Related]
5. Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing.
Truong H; Sheikh R; Kotecha R; Kemel Y; Reisz PA; Lenis AT; Mehta NN; Khurram A; Joseph V; Mandelker D; Latham A; Ceyhan-Birsoy O; Ladanyi M; Shah NJ; Walsh MF; Voss MH; Lee CH; Russo P; Coleman JA; Hakimi AA; Feldman DR; Stadler ZK; Robson ME; Motzer RJ; Offit K; Patil S; Carlo MI
Eur Urol Oncol; 2021 Dec; 4(6):993-1000. PubMed ID: 34654685
[TBL] [Abstract][Full Text] [Related]
6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic Germline Mutational Landscape in Patients With Renal Cell Carcinoma and Associated Clinicopathologic Features.
Nguyen CB; Knaus C; Li J; Accardo ML; Koeppe E; Vaishampayan UN; Alva AS; Else T
JCO Precis Oncol; 2023 Sep; 7():e2300168. PubMed ID: 38127826
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value and potential subtypes of immune activity scores in three major urological cancers.
Shi B; Qi J
J Cell Physiol; 2021 Apr; 236(4):2620-2630. PubMed ID: 32853461
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis of G6PD carcinogenesis in human tumors.
Liu B; Fu X; Du Y; Feng Z; Chen R; Liu X; Yu F; Zhou G; Ba Y
Carcinogenesis; 2023 Aug; 44(6):525-534. PubMed ID: 37335542
[TBL] [Abstract][Full Text] [Related]
10. The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility.
Liu M; Liu X; Suo P; Gong Y; Qu B; Peng X; Xiao W; Li Y; Chen Y; Zeng Z; Lu Y; Huang T; Zhao Y; Liu M; Li L; Chen Y; Zhou Y; Liu G; Yao J; Chen S; Song L
Transl Lung Cancer Res; 2020 Jun; 9(3):646-658. PubMed ID: 32676327
[TBL] [Abstract][Full Text] [Related]
11. A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
Zhang H; Lu X; Huang G; Hua M; Zhang W; Wang T; Huang L; Wang Z; Chen Q; Li J; Yang Q; Yang G
BMC Med Genomics; 2022 Jan; 15(1):1. PubMed ID: 34980126
[TBL] [Abstract][Full Text] [Related]
12. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Characterization of Common and Cancer-Specific Differently Expressed lncRNAs in Urologic Cancers.
Yan YJ; Zhang L; Zhou JJ; Chen ZJ; Liao YX; Zeng JM; Shen H
Comput Math Methods Med; 2021; 2021():5515218. PubMed ID: 34335862
[TBL] [Abstract][Full Text] [Related]
14. Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer.
Wu L; Chaffee KG; Parker AS; Sicotte H; Petersen GM
Tumour Biol; 2015 Sep; 36(10):7431-7. PubMed ID: 25900876
[TBL] [Abstract][Full Text] [Related]
15. System analysis of
Situ Y; Xu Q; Deng L; Zhu Y; Gao R; Lei L; Shao Z
Int J Biol Markers; 2022 Mar; 37(1):90-101. PubMed ID: 34870494
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma.
Carlo MI; Mukherjee S; Mandelker D; Vijai J; Kemel Y; Zhang L; Knezevic A; Patil S; Ceyhan-Birsoy O; Huang KC; Redzematovic A; Coskey DT; Stewart C; Pradhan N; Arnold AG; Hakimi AA; Chen YB; Coleman JA; Hyman DM; Ladanyi M; Cadoo KA; Walsh MF; Stadler ZK; Lee CH; Feldman DR; Voss MH; Robson M; Motzer RJ; Offit K
JAMA Oncol; 2018 Sep; 4(9):1228-1235. PubMed ID: 29978187
[TBL] [Abstract][Full Text] [Related]
17. Inherited mutations in Chinese patients with upper tract urothelial carcinoma.
Wu J; Jin S; Gu C; Wei Y; Zhu Y; Necchi A; Shariat SF; Pan J; Gan H; Dai B; Zhang H; Shi G; Zhu Y; Shen Y; Zhu Y; Ye D
Cell Rep Med; 2023 Jan; 4(1):100883. PubMed ID: 36630951
[TBL] [Abstract][Full Text] [Related]
18. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma.
Santos M; Lanillos J; Roldan-Romero JM; Caleiras E; Montero-Conde C; Cascón A; Climent MA; Anguera G; Hernando S; Laínez N; Robledo M; Robles L; de Velasco G; García-Donas J; Rodriguez-Antona C
Genet Med; 2021 Apr; 23(4):698-704. PubMed ID: 33442023
[TBL] [Abstract][Full Text] [Related]
20. Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease.
Wu J; Wang H; Ricketts CJ; Yang Y; Merino MJ; Zhang H; Shi G; Gan H; Linehan WM; Zhu Y; Ye D
Cancer; 2019 Apr; 125(7):1060-1069. PubMed ID: 30548481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
